We are live on !
Find out more
SL
Siren LLC Portfolio holdings
AUM
$4.94B
Turnover
27.78%
1-Year Est. Return
244.43%
This Fund
S&P 500
This Quarter Est. Return
+34.74%
1 Year Est. Return
+244.43%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.94B
AUM Growth
+$1.33B
(+37%)
Cap. Flow
+$314M
Cap. Flow % of AUM
Cap. Flow %
6.35%
Top 10 Holdings %
Top 10 Hldgs %
44.63%
Holding
126
New
26
Increased
32
Reduced
21
Closed
9
Avg Time Held
Equity + Options
0.9
years
Top 10 Avg Time Held
Equity + Options
0.9
years
Top 20 Avg Time Held
Equity + Options
0.7
years
Avg Time Held Equity only
0.9
years
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PBLS
Parabilis Medicines Inc
PBLS
|
+$82.7M |
| 2 |
Abivax
ABVX
|
+$65.2M |
| 3 |
Hemab Therapeutics
COAG
|
+$57.6M |
| 4 |
Relay Therapeutics
RLAY
|
+$53M |
| 5 |
Kailera Therapeutics
KLRA
|
+$48.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Scholar Rock
SRRK
|
+$60.4M |
| 2 |
Edgewise Therapeutics
EWTX
|
+$42.9M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$41.8M |
| 4 |
Revolution Medicines
RVMD
|
+$30.8M |
| 5 |
Kymera Therapeutics
KYMR
|
+$21.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.94% |
| 2 | Technology | 3.57% |
| 3 | Communication Services | 1.85% |
| 4 | Financials | 0.87% |
| 5 | Consumer Discretionary | 0.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Disc Medicine
IRON
$3.46B
| $65M | 1.32% |
888,401
-100,000
| -10% | -$6.87M |
2025 Q1
5 quarters
|
|
27
Cytokinetics
CYTK
$7.58B
| $64.7M | 1.31% |
758,952
+145,000
| +24% | +$10.4M |
2026 Q1
1 quarter
|
|
28
Septerna Inc
SEPN
$2.26B
| $63.6M | 1.29% |
1,900,000
-100,000
| -5% | -$2.84M |
2024 Q4
6 quarters
|
|
29
Olema Pharmaceuticals
OLMA
$605M
| $60.8M | 1.23% |
4,856,949
+100,000
| +2% | +$1.34M |
2025 Q4
2 quarters
|
|
30
DELISTED
Crinetics Pharmaceuticals
CRNX
| $53.2M | 1.08% |
1,420,788
-482,848
| -25% | -$17.9M |
2024 Q3
7 quarters
|
|
|
31
Kailera Therapeutics
KLRA
$1.59B
| $48.8M | 0.99% |
+2,214,286
| New | +$48.7M |
2026 Q2
0 quarters
|
|
32
Dyne Therapeutics
DYN
$3.35B
| $47.3M | 0.96% |
2,129,125
-100,000
| -4% | -$1.86M |
2024 Q3
7 quarters
|
|
33
Structure Therapeutics
GPCR
$1.33B
| $46.9M | 0.95% |
872,967
-455,731
| -34% | -$20.2M |
2025 Q3
3 quarters
|
|
34
Taboola.com
TBLA
$549M
| $42.1M | 0.85% |
8,423,410
-1,546,085
| -16% | -$6.76M |
2024 Q3
7 quarters
|
|
35
Palvella Therapeutics
PVLA
$2.3B
| $39.3M | 0.8% |
257,485
| – | – |
2025 Q4
2 quarters
|
|
36
Silence Therapeutics
SLN
$1.23B
| $36.4M | 0.74% |
3,311,438
+400,000
| +14% | +$2.81M |
2024 Q3
7 quarters
|
|
37
Denali Therapeutics
DNLI
$3.21B
| $35.9M | 0.73% |
1,396,513
| – | – |
2024 Q3
7 quarters
|
|
38
Remitly
RELY
$4.59B
| $34.6M | 0.7% |
1,543,271
| – | – |
2024 Q3
7 quarters
|
|
39
Cullinan Oncology
CGEM
$709M
| $34.5M | 0.7% |
1,893,410
+700,000
| +59% | +$10.4M |
2024 Q3
7 quarters
|
|
40
Capital One
COF
$123B
| $34.4M | 0.7% |
+171,615
| New | +$32.8M |
2026 Q2
0 quarters
|
|
41
Trevi Therapeutics
TRVI
$1.91B
| $33.3M | 0.67% |
1,786,867
| – | – |
2024 Q4
6 quarters
|
|
42
Oric Pharmaceuticals
ORIC
$889M
| $32.5M | 0.66% |
2,998,192
| – | – |
2024 Q3
7 quarters
|
|
43
Alphabet (Google) Class A
GOOGL
$3.52T
| $32.2M | 0.65% |
90,000
+24,297
| +37% | +$8.75M |
2024 Q3
7 quarters
|
|
44
DBV Technologies S.A. American Depositary Shares
DBVT
$611M
| $30.5M | 0.62% |
1,857,362
| – | – |
2025 Q4
2 quarters
|
|
45
Absci
ABSI
$1.65B
| $28.7M | 0.58% |
2,474,764
+674,764
| +37% | +$3.8M |
2026 Q1
1 quarter
|
|
46
Sionna Therapeutics
SION
$149M
| $26.9M | 0.54% |
610,515
+310,515
| +104% | +$12.4M |
2025 Q1
5 quarters
|
|
47
Rapport Therapeutics
RAPP
$1.41B
| $26.7M | 0.54% |
641,469
| – | – |
2024 Q3
7 quarters
|
|
48
Amylyx Pharmaceuticals
AMLX
$3.56B
| $26.6M | 0.54% |
1,480,586
+250,586
| +20% | +$3.88M |
2026 Q1
1 quarter
|
|
49
Annexon
ANNX
$791M
| $25.5M | 0.52% |
4,458,646
+500,000
| +13% | +$2.76M |
2026 Q1
1 quarter
|
|
50
Monopar Therapeutics
MNPR
$460M
| $25M | 0.51% |
270,118
| – | – |
2025 Q4
2 quarters
|
|
Similar funds
Siren LLC's Q2 2026 Portfolio in Review
As of Q2 2026, Siren LLC held 126 positions worth $4.94B, up 37% from $3.61B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Siren LLC deployed $314M of net new capital in Q2 2026, opening 26 new positions and adding to 32 existing holdings. Its largest new stake was Parabilis Medicines Inc: 2,992,259 shares worth $81.9M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Scholar Rock, an estimated $60.4M trimmed.
- Siren LLC's largest Q2 2026 buy was Parabilis Medicines Inc: 2,992,259 shares worth $81.9M.
- Siren LLC added most to Enliven Therapeutics in Q2 2026, an estimated $43.7M increase.
- Siren LLC's biggest Q2 2026 reduction was Scholar Rock, cutting an estimated $60.4M.
- Siren LLC fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $41.8M.
- Siren LLC's ten largest holdings make up 45% of its $4.94B portfolio in Q2 2026.
- Siren LLC opened 26 new positions and closed 9 in Q2 2026.
- Siren LLC's portfolio value rose 37% quarter-over-quarter to $4.94B.
Based on Siren LLC's 13F filing for Q2 2026, filed 13 Aug 2026.